Skin | Page 63 of 109 | SpiritIndia.com

Inflammatory Disease :: Array BioPharma’s MEK Inhibitor, ARRY-438162, meets initial clinical objectives

Array BioPharma Inc. (Nasdaq: ARRY) announced that its first-in-class MEK inhibitor for the treatment of inflammatory diseases, ARRY-438162, has met its primary objectives in a single ascending dose clinical study involving 20 healthy volunteers. These results were presented by Array?s President and Chief Scientific Officer, Kevin Koch, Ph.D., at the 14th International Inflammation Research Association Conference in Cambridge, Maryland.

Lung Cancer :: GALES Trial of ALIMTA, pemetrexed for injection in Small Cell Lung Cancer

Eli Lilly and Company has launched a major clinical trial evaluating ALIMTA (pemetrexed for injection) in extensive-stage small cell lung cancer (SCLC), a devastating and rapidly spreading form of lung cancer. This international trial, expected to be the largest ever to be conducted in SCLC(1), will assess the potential clinical benefit of pemetrexed in combination with carboplatin, a commonly-used chemotherapeutic agent, in direct comparison to the current leading treatment option of etoposide in combination with carboplatin.

Herpes :: Human Protein Helps Chickenpox and Shingles Virus Spread

A team of scientists at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), has identified a human protein that helps varicella-zoster virus, the cause of both chickenpox and shingles, spread from cell to cell within the body.

Skin Cancer :: Skin cancer prevention – beachgoers accurately report their sun habits

Adult beachgoers participating in a research study accurately report their sun habits, including sunscreen use and clothing worn on the beach, according to a report in the October issue of Archives of Dermatology, one of the JAMA/Archives journals. The skin cancer cutaneous melanoma has become much more common and deadly in the United States over the past few decades, according to background information in the article.

Colorectal Cancer :: Grape seeds – cancer fighter in colorectal tumors

Grape seed extract significantly inhibited the growth of colorectal tumors in both laboratory cell cultures and in mice, U.S. researchers report. A team from the University of Colorado Health Sciences Center in Denver says mice given the extract displayed a 44 percent reduction in the size of advanced colorectal tumors.

Skin Cancer :: New technique to diagnose skin cancer spread – photoacoustic detection

In the future doctors may be able to detect the spread of cancer by simply listen for it, researchers reported on Tuesday. Researchers at the University of Missouri-Columbia said they used a technique called photoacoustic detection to pick up the characteristic vibrations of melanoma cells in the blood.

Breast Cancer :: Breast-cancer revelation not solely limited to detecting lumps

Women should be aware that not every type of breast cancer reveals itself with a lump during self exams. An aggressive, fast-spreading form called inflammatory breast cancer (IBC) grows in nests or sheets of cancer cells that spread through the breast. Because it is relatively rare, IBC is often diagnosed late or even misdiagnosed as an infection.

ADHD :: Preschoolers with ADHD Improve with Low Doses of Medication

The first long-term, large-scale study designed to determine the safety and effectiveness of treating preschoolers who have attention deficit/hyperactivity disorder (ADHD) with methylphenidate (Ritalin) has found that overall, low doses of this medication are effective and safe. However, the study found that children this age are more sensitive than older children to the medication?s side effects and therefore should be closely monitored. The 70-week, six-site study was funded by the National Institutes of Health?s National Institute of Mental Health (NIMH) and was described in several articles in the November 2006 issue of the Journal of the American Academy of Child and Adolescent Psychiatry.

Allergy :: Experimental Ragweed Therapy Offers Allergy Sufferers Longer Relief with Fewer Shots

Americans accustomed to the seasonal misery of sneezing, runny noses and itchy, watery eyes caused by ragweed pollen might one day benefit from an experimental allergy treatment that not only requires fewer injections than standard immunotherapy, but leads to a marked reduction in symptoms that persists for at least a year after therapy has stopped, according to a new study in the October 5 issue of The New England Journal of Medicine (NEJM). The research was sponsored by the Immune Tolerance Network, which is funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both components of the National Institutes of Health (NIH), and the Juvenile Diabetes Research Foundation International.

Muscular Dystrophy :: Drug Trichostatin A (TSA) Can Counteract Muscular Dystrophy

Scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other institutions have demonstrated for the first time that a single drug can rebuild damaged muscle in two strains of mice that develop diseases comparable to two human forms of muscular dystrophy. This advance, which is reported online in Nature Medicine, is the latest from a research collaboration that began several years ago by the teams of Vittorio Sartorelli, M.D., at NIAMS and Pier Lorenzo Puri, M.D., Ph.D., now at Dulbecco Telethon Institute (DTI) in Rome, Italy and The Burnham Institute in La Jolla, Calif.